125 related articles for article (PubMed ID: 36960837)
1. Iatrogenic symptomatic hypoadrenocorticism after treatment with trilostane for hyperadrenocorticism in dogs: eight cases (2008-2019).
Lamoureux A; Cadoré JL; Hugonnard M; Chabanne L; Krafft E
J Small Anim Pract; 2023 Jun; 64(6):409-414. PubMed ID: 36960837
[TBL] [Abstract][Full Text] [Related]
2. Incidence and risk factors for hypoadrenocorticism in dogs treated with trilostane.
King JB; Morton JM
Vet J; 2017 Dec; 230():24-29. PubMed ID: 29208212
[TBL] [Abstract][Full Text] [Related]
3. Persistent isolated hypocortisolism following brief treatment with trilostane.
Ramsey IK; Richardson J; Lenard Z; Tebb AJ; Irwin PJ
Aust Vet J; 2008 Dec; 86(12):491-5. PubMed ID: 19076773
[TBL] [Abstract][Full Text] [Related]
4. Adrenal necrosis in a dog receiving trilostane for the treatment of hyperadrenocorticism.
Chapman PS; Kelly DF; Archer J; Brockman DJ; Neiger R
J Small Anim Pract; 2004 Jun; 45(6):307-10. PubMed ID: 15206477
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Iatrogenic Hypocortisolemia Following Trilostane Therapy in 48 Dogs with Pituitary-Dependent Hyperadrenocorticism.
Appleman E; Schrage A; Lamb KE; Langston C
J Am Anim Hosp Assoc; 2021 Sep; 57(5):217-224. PubMed ID: 34370857
[TBL] [Abstract][Full Text] [Related]
6. Trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism.
Braddock JA; Church DB; Robertson ID; Watson AD
Aust Vet J; 2003 Oct; 81(10):600-7. PubMed ID: 15080470
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of low- and high-dose trilostane treatment in dogs (< 5 kg) with pituitary-dependent hyperadrenocorticism.
Cho KD; Kang JH; Chang D; Na KJ; Yang MP
J Vet Intern Med; 2013; 27(1):91-8. PubMed ID: 23167780
[TBL] [Abstract][Full Text] [Related]
8. Pre-trilostane and three-hour post-trilostane cortisol to monitor trilostane therapy in dogs.
Macfarlane L; Parkin T; Ramsey I
Vet Rec; 2016 Dec; 179(23):597. PubMed ID: 27803375
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of twice-daily lower-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism.
Feldman EC
J Am Vet Med Assoc; 2011 Jun; 238(11):1441-51. PubMed ID: 21627507
[TBL] [Abstract][Full Text] [Related]
10. Cortisol Concentrations in Well-Regulated Dogs with Hyperadrenocorticism Treated with Trilostane.
Midence JN; Drobatz KJ; Hess RS
J Vet Intern Med; 2015; 29(6):1529-33. PubMed ID: 26374943
[TBL] [Abstract][Full Text] [Related]
11. Results of clinical examinations, laboratory tests, and ultrasonography in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane.
Ruckstuhl NS; Nett CS; Reusch CE
Am J Vet Res; 2002 Apr; 63(4):506-12. PubMed ID: 11939311
[TBL] [Abstract][Full Text] [Related]
12. Histological evaluation of the adrenal glands of seven dogs with hyperadrenocorticism treated with trilostane.
Reusch CE; Sieber-Ruckstuhl N; Wenger M; Lutz H; Perren A; Pospischil A
Vet Rec; 2007 Feb; 160(7):219-24. PubMed ID: 17308018
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival of dogs with adrenal-dependent hyperadrenocorticism: a comparison between mitotane and twice daily trilostane treatment.
Arenas C; Melián C; Pérez-Alenza MD
J Vet Intern Med; 2014; 28(2):473-80. PubMed ID: 24495125
[TBL] [Abstract][Full Text] [Related]
14. Update on the use of trilostane in dogs.
Lemetayer J; Blois S
Can Vet J; 2018 Apr; 59(4):397-407. PubMed ID: 29606727
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of 2 trilostane protocols for the treatment of canine pituitary-dependent hyperadrenocorticism: twice daily versus once daily.
Arenas C; Melián C; Pérez-Alenza MD
J Vet Intern Med; 2013; 27(6):1478-85. PubMed ID: 24118316
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the use of baseline cortisol concentration as a monitoring tool for dogs receiving trilostane as a treatment for hyperadrenocorticism.
Cook AK; Bond KG
J Am Vet Med Assoc; 2010 Oct; 237(7):801-5. PubMed ID: 20919845
[TBL] [Abstract][Full Text] [Related]
17. Comparison of adrenocorticotropic hormone stimulation test results started 2 versus 4 hours after trilostane administration in dogs with naturally occurring hyperadrenocorticism.
Bonadio CM; Feldman EC; Cohen TA; Kass PH
J Vet Intern Med; 2014; 28(4):1239-43. PubMed ID: 24863172
[TBL] [Abstract][Full Text] [Related]
18. Changes in ultrasonographic appearance of adrenal glands in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane.
Mantis P; Lamb CR; Witt AL; Neiger R
Vet Radiol Ultrasound; 2003; 44(6):682-5. PubMed ID: 14703251
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy of trilostane administered twice daily in dogs with pituitary-dependent hyperadrenocorticism.
Alenza DP; Arenas C; Lopez ML; Melian C
J Am Anim Hosp Assoc; 2006; 42(4):269-76. PubMed ID: 16822765
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of compounded trilostane packets for dogs with naturally occurring hyperadrenocorticism.
Nam S; Kim TW; Song KH; Feldman EC; Seo KW
J Vet Intern Med; 2021 Jul; 35(4):1729-1732. PubMed ID: 34114230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
